Urba, W. J., J. Nemunaitis, et al. ( 2008). "Treatment of re current, hormone-naïve, prostate cancer with GM-CSF-secreting, allogeneic, cellular immunotherapy." J Urol(submitted). 212. Vagenas, K., C. Spyropoulos, et al. (2007). "TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival." J Surg Res 139(2): 182-8. 213. Van den Eynde B, H. P., Herin M, et al (1989). "Presence on a human melanoma of multiple antigens recognized by autologous CTL." Int J Cancer 44: 634-40. 214. Walden, P. (2007). "Therapeutic vaccinat ion for the treatment of malignant melanoma." Recent Results Cancer Res 176: 219-27. 215. Woo, E. Y., H. Yeh, et al. (2002). "Cutting edge: Regulatory T cells from lung cancer patients directly inhibit auto logous T cell prolifer ation." J Immunol 168 (9): 4272-6. 216. Wu, X., Q. M. Feng, et al. (2010). "The immunologic aspects in advanced ovarian cancer patients treated wit h paclitaxel and carboplatin chemotherapy." Cancer Immunol Immunother 59(2): 279-91. 217. Yamada, N., M. Kato, et al. (1995). "Enhanced expression of transforming growth factor-beta and its type-I and type-II recept ors in human glioblastoma." Int J Cancer 62(4): 386-92. 218. Yamaguchi, H., K. Furukawa, et al . (1990). "Human monoc lonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient." Proc Natl Acad Sci U S A 87(9): 3333-7. 219. Yamaguchi, Y., H. Tsumura, et al. ( 1997). "Contrasting effect s of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow." Stem Cells 15(2): 144-53. Protocol # CL-PTL 105 CONFIDENTIAL AM #9 09/25/15 Page 95 220.